Show Less
You do not have access to this content

Advanced Introduction to International Intellectual Property

Susy Frankel and Daniel J. Gervais

This authoritative introduction provides a detailed overview of the complexities of the international intellectual property regime and the ways in which it operates. The authors cover the key international institutions and agreements that regulate and inform intellectual property at an international level such as the TRIPS Agreement, WIPO, WTO, the Paris Convention and the Berne Convention.
Show Summary Details
You do not have access to this content

1 The institutions and actors of international intellectual property

Susy Frankel and Daniel J. Gervais


The two main multilateral intergovernmental institutions in the field of intellectual property at the multilateral level are WIPO and the WTO. A number of other intergovernmental institutions are also active in the field, including the United Nations Educational, Scientific and Cultural Organization (UNESCO) on matters such as cultural heritage and education; the World Health Organization (WHO) on matters concerning pharmaceutical and medical research and access to medicines; the International Labour Office (ILO) on matters concerning the rights of performing artists; and the secretariat of the Convention on Biological Diversity (CBD) and its Nagoya Protocol on matters relating to uses of biological and genetic resources and the protection of related traditional knowledge.

A number of non-governmental organizations (NGOs) are also extremely active at the international level.7 They include organizations representing “right holders” such as pharmaceutical companies, entertainment conglomerates, and luxury brand owners, but also small inventors, songwriters, film makers, actors and performing artists. Some represent indigenous communities that have an interest in protecting their indigenous cultural and medicinal heritage. Even within an industry, not everyone may have similar interests. For example, the software industry includes companies seeking high levels of protection of intellectual property, while others have business models that rely on “open source” software or the possibility of using material created by others. Within the pharmaceutical industry, the companies that spend some part of their profits on research and drug development do not always see “eye-to-eye” with those that produce generic drugs (drugs that are not or no...

You are not authenticated to view the full text of this chapter or article.

Elgaronline requires a subscription or purchase to access the full text of books or journals. Please login through your library system or with your personal username and password on the homepage.

Non-subscribers can freely search the site, view abstracts/ extracts and download selected front matter and introductory chapters for personal use.

Your library may not have purchased all subject areas. If you are authenticated and think you should have access to this title, please contact your librarian.

Further information

or login to access all content.